Reimbursed Care Access in Switzerland

Switzerland permits clinical/therapeutic use of psilocybin under a formal exceptional‑use / treatment authorisation process administered by federal health authorities; psychiatrists may apply for individual treatment authorisations for psychedelic‑assisted psychotherapy rather than rely on a market‑authorised drug product. This framework has been in active use for years and Swiss clinicians report hundreds of individual authorisations (clinical treatment authorisations) for psilocybin in recent years, with patients required to receive psychotherapy together with the drug and treatments generally delivered in private practices or specialised institutions. # #

Reimbursement/status: There is no broad, automatic public reimbursement pathway equivalent to a market‑authorised, labelled medicine paid across the mandatory basic health insurance; access is provided through individual/exceptional authorisations and delivered largely in private or specialised settings. Patients and providers should assume costs and reimbursement will be handled case‑by‑case; formal national reimbursement lines for psilocybin as a conventional medicine are not the standard mechanism in Switzerland. #

MDMA can be prescribed/used within Switzerland under the same exceptional/individual authorisation mechanism for psychedelic‑assisted psychotherapy: clinicians must obtain case‑by‑case approval from federal authorities to administer MDMA alongside psychotherapy for specified indications (for example, PTSD in specialist protocols). Swiss reporting indicates hundreds of such treatment authorisations (MDMA among the substances specifically granted under the exceptional framework). # #

Reimbursement/status: MDMA is not a widely market‑authorised, reimbursed product in routine ambulatory care. Access is organised through authorised specialised treatment programs or individual approvals; reimbursement and cost coverage are therefore determined case‑by‑case and are typically tied to private clinic arrangements or individual negotiations with insurers rather than a standard automatic reimbursement under the basic health insurance scheme.

Esketamine (Spravato®) is authorised in Switzerland: Swissmedic granted marketing authorisation for esketamine nasal spray (Spravato) with labelled indications including treatment‑resistant depression (initial authorisation 25 February 2020; subsequent summary and indication information published by Swissmedic). The Swissmedic Public Summary (SwissPAR) documents the authorised indication(s), required monitoring conditions (administration under supervised clinical settings with post‑dosing observation), and safety considerations. # #

Reimbursement/status: Spravato is a market‑authorised medicinal product in Switzerland; however, whether costs are covered by a patient’s mandatory basic health insurance (LaMal/KVG) or by supplemental/private insurers depends on the specific indication, invoicing, and the insurer’s assessment of medical necessity and treatment setting. Swissmedic authorisation is a prerequisite for standard reimbursement processes, but individual coverage decisions are made by payers according to Swiss health‑insurance regulation and tariff rules.

Ketamine is an established, legal medicinal agent in Switzerland when used for licensed indications (anaesthesia) and may be used off‑label by medical professionals for psychiatric indications (e.g., acute or treatment‑resistant depression) in controlled, clinical settings. Off‑label/compassionate uses of ketamine infusions for depression are practised by some Swiss clinics and hospitals under medical supervision; such use is governed by ordinary medical practice rules and professional oversight. #

Reimbursement/status: Off‑label ketamine psychiatric use is generally not uniformly reimbursed by the mandatory basic insurance and is often delivered in private or specialised clinics; coverage depends on insurer policies, whether treatment is delivered within hospital inpatient/outpatient tariffs, and on demonstration of medical necessity—therefore reimbursement is typically determined case‑by‑case rather than automatic. Providers generally document indication, prior treatment failures, and rationale when seeking payer coverage.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research; plant preparations containing DMT (ayahuasca) are treated as containing a controlled tryptamine and are not broadly exempted for religious use in Switzerland. # #

Currently classified as a strictly controlled substance under national drug scheduling laws, with no authorized medical use outside of approved clinical research.

Most substituted phenethylamines in the 2C family (for example 2C‑B) are listed in Swiss controlled‑substance annexes and thus illegal to possess or supply outside authorised research or specific exceptional authorisations; there is no authorised medical/therapeutic use for 2C‑X compounds in routine care. #